Back to News
investment

General Mills: Flat-Sales Bias Masks An Overvalued Stock

Seeking Alpha
Loading...
2 min read
0 likes
Untitled design (26).png
Quantum News · Media Library

Brendan O'Boyle2.73K FollowersFollow5ShareSavePlay(12min)CommentsSummaryGeneral Mills is rated "Sell" due to persistent revenue decline, deteriorating balance sheet, and secular headwinds challenging its business model.FY26 guidance forecasts a 2% to 1.5% organic sales decline and a 20% to 16% adjusted EPS drop, with free cash flow also falling.Share repurchases have abruptly ceased, signaling capital preservation mode as liabilities reach $23.22 billion to an uncomfortable 6.56x EBITDA.With negative growth, high leverage, and eroding consumer demand, GIS offers little upside versus diversified dividend ETFs. FotografiaBasica/iStock Unreleased via Getty Images Yesterday, General Mills, Inc. (GIS) provided a financial update ahead of presenting at the Consumer Analyst Group of New York Conference (CAGNY). The guidance underperformed already low expectations, with management seeing organic sales, operating profit, and cash flow all falling in FY26.This article was written byBrendan O'Boyle2.73K FollowersFollowBrendan, a Pennsylvanian by birth:-Completed a Ph.D. at Stanford University in the field of organic synthesis (2009). -Worked for a major pharmaceutical company (Merck, 2009-2013).-Worked in biotech including start-ups (Theravance/Aspira) prior to securing employment at Caltech.-First employee and co-founder of 1200 Pharma as it spun out of Caltech garnering major investment (into the 8 figures).-Remains an avid investor, focused on market trends and especially biotechnology stocks.Analyst’s Disclosure: I/we have a beneficial long position in the shares of DGRO either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. The author is long DGRO with no plans to initiate a position in GIS.Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Read Original

Tags

drug-discovery

Source Information

Source: Seeking Alpha

Discussion

0 professional contributions

Sign in to join this professional discussion.

Be the first to add a constructive contribution.